The use of comprehensive molecular profiling to identify patients most likely to benefit from immunotherapy and warrant validation in prospective clinical trials is supported, and encouraging clinical activity in selected CAYAs with solid tumors when guided by tumor-specific biomarkers is demonstrated.
Andy Huy-Dat Vu, M. Brizini, M. Brisson et al.· Cancer Research· 0 citations
Histone 3 lysine 27-to-methionine substitutions (H3K27M) drive aggressive diffuse midline gliomas by blocking differentiation of radial glial progenitor cells committed to oligodendrogenesis. We establish prolonged differentiation as a powerful tool to uncover regulators of glioma cell states and demonstrate that t...
Alan L. Jiao, Abolfazl Maghrouni, A. Gutiérrez et al.· Nature Communications· 0 citations
Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have large...
Anna Borgenvik, Sean A. Misek, Daniel Christen et al.· bioRxiv· 1 citation
It is shown that ablation of Usp15 in astrocytes and in microglia protects against lethal neuroinflammation in vivo, and a strong cis-acting eQTL directing high USP15 expression in CD14+ myeloid cells is detected in humans.
Nassima Fodil, E. del Cid-Pellitero, V. Piscopo et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
